Mizuho analyst Ann Hynes raised the firm’s price target on HCA Healthcare to $279 from $265 and keeps a Buy rating on the shares. The analyst says the company’s underlying demand trends continued to improve sequentially in Q4 and that its 2023 outlook appears conservative.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare sees FY23 EPS $16.40-$17.60, consensus $18.23
- HCA Healthcare reports Q4 EPS $4.64, consensus $4.78
- HCA Healthcare price target raised to $296 from $237 at UBS
- HCA Healthcare price target raised to $270 from $240 at Truist
- HCA Healthcare price target raised to $275 from $240 at Deutsche Bank